Health Care & Life Sciences » Pharmaceuticals | SymBio Pharmaceuticals Ltd.

SymBio Pharmaceuticals Ltd. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
Sales/Revenue
1,532
1,955
1,933
2,368
3,444
Cost of Goods Sold (COGS) incl. D&A
1,221
1,437
1,362
1,475
2,424
Gross Income
311
518
571
893
1,020
SG&A Expense
1,868
1,821
3,123
3,020
4,967
EBIT
1,556
1,303
2,552
2,127
3,947
Unusual Expense
-
2
3
9
3
Non Operating Income/Expense
69
165
96
196
33
Interest Expense
-
-
-
-
-
Pretax Income
1,601
1,112
2,628
2,309
3,974
Income Tax
4
4
4
4
4
Consolidated Net Income
1,605
1,116
2,632
2,313
3,978
Net Income
1,605
1,116
2,632
2,313
3,978
Net Income After Extraordinaries
1,605
1,116
2,632
2,313
3,978
Net Income Available to Common
1,605
1,116
2,632
2,313
3,978
EPS (Basic)
69.29
36.26
81.26
58.82
79.78
Basic Shares Outstanding
23
31
32
39
50
EPS (Diluted)
69.29
36.26
81.26
58.82
79.78
Diluted Shares Outstanding
23
31
32
39
50
EBITDA
1,548
1,291
2,527
2,101
3,917
Non-Operating Interest Income
10
25
16
5
3

About SymBio Pharmaceuticals

View Profile
Address
Toranomon 30 Mori Building
Tokyo Tokyo 105
Japan
Employees -
Website http://www.symbiopharma.com
Updated 09/14/2018
SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded on March 25, 2005 by Fuminori Yoshida and is headquartered in Tokyo, Japan.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.